Osimertinib Plus Chemo Increases PFS, First Line Toxicity.

Published Date: 16 Sep 2023

Osimertinib and chemotherapy together improved progression-free survival in non-small cell lung cancer patients with EGFR mutations, according to new interim data, but toxicity concerns have been voiced by experts.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Does pollution cause cancer?

2.

AI is equally capable of reading breast cancer scans as human radiologists.

3.

EVP Beats Cisplatin for Resectable MIBC

4.

New research points out a promising strategy for treating metastatic medulloblastoma

5.

Academics + Pharma = Big Bucks; New CAR-T Warnings; Patients Seek Cancer Tests.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot